Ophthalmology
Medical Education
Pre-Med: University of Bombay, Bombay, India, 1986
Medical Degree: L.T.M. Medical College, University of Bombay, Bombay, India, 1992
Ph.D.: Cellular and Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, 1997
Residency: Ophthalmology, UT Southwestern Medical Center, Dallas, Texas , 2001
Fellowship: Retinal Vascular, Wilmer Ophthalmological Institute, Baltimore, Maryland, 2002
Fellowship: Vitreoretinal, Wilmer Ophthalmological Institute, Baltimore, Maryland, 2003
Honors and Awards
Executive Committee Member, The Macula Society
Washington University Nominee for the Ellison Foundation New Scholars Award in Aging, 2005
Disclosure of Financial Interests with IndustryWashington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.
Dr. Rajendra S. Apte reported the following earned financial interests during calendar year 2011. Move your mouse over a header for more info.
| Company | Royalties Royalties: When a faculty member invents or conceives a new or improved process or product, the company that manufactures the product will make royalty payments to the faculty member. Royalty payments usually are a small percentage of the company’s revenue related to that product. | Consulting &
Advisory Boards Consulting and Advisory Boards: Faculty may be paid to provide expertise to a company by being their consultant, or by serving on an advisory board. | Speaker Fees Speaker Fees: Companies may pay faculty to speak to professional audiences about their products. |
| Genentech | | $1,000-$10,000 | $25,001-$50,000 |
| Regeneron | | $1,000-$10,000 | $10,001-$25,000 |
To learn more about Washington University's policies on collaborations with industry,
click here.
Selected or Recent Journal Articles
Dewan V, Lambert D, Edler J, Kymes S, Apte RS. "Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema." Ophthalmology. 2012 Aug;119(8):1679-84.
Kraus CL, Rao PK, Apte RS. "Effect of preoperative vitreous status on visual outcomes following vitrectomy for epiretinal membrane repair." Can J Ophthalmol. 2011 Apr;46(2):186-90.
Sheybani A, Brantley MA Jr, Apte RS. "Pattern electroretinography in age-related macular degeneration." Arch Ophthalmol. 2011 May;129(5):580-4.
Schimel AM, Abraham L, Cox D, Sene A, Kraus C, Dace DS, Ercal N, Apte RS. "N-acetylcysteine amide (NACA) prevents retinal degeneration by up-regulating reduced glutathione production and reversing lipid peroxidation." Am J Pathol. 2011 May;178(5):2032-43.
Apte RS, Alexander SL, Henry EC, Wong P, Tuomi L. "An observational retrospective subgroup analysis of verteporfin photodynamic therapy-naive and previously treated patients in the focus trial." Retina. 2011 Jan;31(1):56-64.
Khan AA, Dace DS, Ryazanov AG, Kelly J, Apte RS. "Resveratrol regulates pathologic angiogenesis by a eukaryotic elongation factor-2 kinase-regulated pathway." Am J Pathol. 2010 Jul;177(1):481-92.
Rajagopal R, Apte RS. "Full-thickness macular hole in a patient with proliferative sickle cell retinopathy." Retina. 2010 May;30(5):838-9.
Apte RS. "Regulation of angiogenesis by macrophages." Adv Exp Med Biol. 2010;664: 15-9.
Roychoudhury J, Herndon JM, Yin J, Apte RS, Ferguson TA. "Targeting immune privilege to prevent pathogenic neovascularization." Invest Ophthalmol Vis Sci. 2010 Jul;51(7): 3560-6.
Dace DS, Khan AA, Stark JL, Kelly J, Cross AH, Apte RS. "Interleukin-10 overexpression promotes Fas-ligand-dependent chronic macrophage-mediated demyelinating polyneuropathy." PLoS One. 2009 Sep 22;4(9):e7121.
Smith BT, Kraus CL, Apte RS. "Retinal pigment epithelial tears in ranibizumab-treated eyes." Retina. 2009 Mar;29(3):335-9.
Khan AA, Apte RS. "An assay for macrophage-mediated regulation of endothelial cell proliferation." Immunobiology. 2008;213(9-10):695-9.
Dace DS, Khan AA, Kelly J, Apte RS. "Interleukin-10 promotes pathological angiogenesis by regulating macrophage response to hypoxia during development." PLoS One. 2008;3(10):e3381.
Schadlu R, Blinder KJ, Shah GK, Holekamp NM, Thomas MA, Grand MG, Engelbrecht NE, Apte RS, Joseph DP, Prasad AG, Smith BT, Sheybani A. "Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis." Am J Ophthalmol. 2008 May;145(5):875-8.
Ferguson TA, Apte RS. "Angiogenesis in eye disease: immunity gained or immunity lost?" Semin Immunopathol. 2008 Apr;30(2):111-9.
For more articles and abstracts, take this off-site link to the National Library of Medicine Pub Med page for Dr. Rajendra S. Apte.